Market Overview

Cytokinetics Downgraded On Data Delay

Share:
Cytokinetics Downgraded On Data Delay

Biopharma Cytokinetics Inc. (NASDAQ: CYTK) announced a delay in drug studies during its earnings call Thursday, prompting a downgrade by Morgan Stanley. 

The Analysts

Morgan Stanley's Matthew Harrison downgraded Cytokinetics from Overweight to Equal-Weight and lowered the price target from $18 to $9.

The Thesis

Morgan Stanley's valuation for Cytokinetics is partly driven by the base value in omecamtiv mecarbil, the company’s cardiac myosin activator, which is being studied for heart failure, Harrison said. (See the analyst's track record here.) 

Key data for this treatment is unlikely for a few years.

Cytokinetics additionally announced that data for reldesemtiv in the large ALS study will be delayed, with data expected in early 2019.

This delay is due to the patient availability and uptake of Radicava, an ALS treatment, according to the biotech. 

The main catalysts for Cytokinetics are near-term, and the stock is ikely to trade evenly with the market until advancements are nearer, Harrison said. 

In the midst of the delays, Galactic-HF, an omecamtiv mecarbil program in heart failure, is on track with over 50-percent enrollment and 4,000 patients, according to Morgan Stanley. 

"We remain positive on the Amgen, Inc. (NASDAQ: AMGN)-partnered program and believe the study is likely to succeed," Harrison said. 

Price Action

Cytokinetics shares were losing 9.18 percent and trading at $6.68 off the open Wednesday.

Related Links

Why Is Cytokinetics Plunging Today?

Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Latest Ratings for CYTK

DateFirmActionFromTo
Oct 2020Morgan StanleyMaintainsOverweight
Oct 2020HC Wainwright & Co.MaintainsBuy
Jul 2020Piper SandlerMaintainsOverweight

View More Analyst Ratings for CYTK
View the Latest Analyst Ratings

 

Related Articles (CYTK)

View Comments and Join the Discussion!

Posted-In: Matthew Harrison Morgan StanleyAnalyst Color Biotech Downgrades Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com